GFAP and proximal spinal muscular atrophy: The aim of this study was to evaluate GFAP concentration in CSF (cGFAP) as a biomarker for disease severity and treatment monitoring in patients with SMA and to further investigate the non‐neuronal involvement in the pathophysiology of SMA.